Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

XORTX Therapeutics Inc

Healthcare US XRTX

2.17USD
-0.08(3.56%)

Last update at 2026-06-05T20:00:00Z

Day Range

2.172.32
LowHigh

52 Week Range

1.987.52
LowHigh

Fundamentals

  • Previous Close 2.25
  • Market Cap7.56M
  • Volume12730
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.85884M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.39

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -6.98888M -1.29589M -1.28460M -0.62958M -3.77592M
Minority interest - - - - -
Net income -6.98888M -1.29589M -1.28460M -0.62958M -3.77592M
Selling general administrative 2.29M 1.58M 1.10M 0.51M 0.80M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.06M 0.02M 0.02M 0.02M 0.02M
Ebit -10.68761M -4.13578M -1.30050M -0.56597M -1.15722M
Ebitda -10.63215M -4.12176M -1.28006M -0.54607M -1.13790M
Depreciation and amortization 0.06M 0.01M 0.02M 0.02M 0.02M
Non operating income net other - - - - -
Operating income -10.68761M -4.13578M -1.30050M -0.56597M -1.15722M
Other operating expenses 9.86M 2.86M 1.30M 0.57M 1.16M
Interest expense 0.00000M 0.00439M 0.01M 0.04M 0.02M
Tax provision - - - - -
Interest income 0.10M - - - -
Net interest income -0.82535M -1.62928M -0.01351M -0.03721M -0.02230M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00000M 0.00439M 0.01M 0.04M 0.02M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 9.86M 2.86M 1.30M 0.57M 1.16M
Cost of revenue - - - - -
Total other income expense net 3.70M 2.84M 0.03M -0.02640M -2.59641M
Discontinued operations - - - - -
Net income from continuing ops -6.98888M -1.65228M -1.28460M -0.62958M -3.77592M
Net income applicable to common shares -9.48531M -1.65228M -1.28460M -0.62958M -3.77592M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 5.47M 12.34M 17.28M 2.29M 1.09M
Intangible assets 0.18M 0.20M 0.20M 0.23M 0.27M
Earning assets - - - - -
Other current assets - - 0.71M 1.61M 0.74M
Total liab 0.83M 5.37M 4.16M 1.03M 1.30M
Total stockholder equity 4.64M 6.97M 13.13M 1.26M -0.21172M
Deferred long term liab - - - - -
Other current liab 0.09M 0.15M 3.83M 0.64M 0.64M
Common stock 17.06M 15.18M 15.69M 8.26M 5.86M
Capital stock 17.06M 15.18M 20.01M 8.26M 5.86M
Retained earnings -17.85491M -14.12879M -7.60010M -8.03800M -6.75860M
Other liab - 5.22M 4.60M - -
Good will - - - - -
Other assets - 0.00000M 0.00000M - -
Cash 3.45M 10.41M 14.79M 0.17M 0.06M
Cash and equivalents - - - - -
Total current liabilities 0.29M 1.51M 4.16M 1.03M 1.30M
Current deferred revenue - - - - -
Net debt -3.43615M -10.33040M -14.78506M -0.17127M -0.00780M
Short term debt 0.01M 0.07M - - 0.05M
Short long term debt - - - - 0.05M
Short long term debt total 0.01M 0.08M - - 0.05M
Other stockholder equity 5.49M 5.92M 5.03M 1.04M 0.68M
Property plant equipment - 0.13M - - 0.00034M
Total current assets 4.07M 10.87M 15.82M 2.06M 0.82M
Long term investments - - - - -
Net tangible assets - 9.20M 16.48M 1.02M -0.48411M
Short term investments - - - - -
Net receivables 0.06M 0.08M 0.04M 0.01M 0.02M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.20M 1.30M 0.32M 0.39M 0.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.05260M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.20M 1.18M 1.26M - -
Deferred long term asset charges - - - - -
Non current assets total 1.40M 1.48M 1.46M 0.23M 0.27M
Capital lease obligations 0.01M 0.08M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.04422M -0.03981M -0.01435M -0.00704M -0.15481M
Change to liabilities 1.26M -0.33321M 0.41M 0.35M -0.02209M
Total cashflows from investing activities -0.06002M -0.03981M -0.01435M -0.00704M -0.15481M
Net borrowings -0.05513M -0.05513M -0.05513M -0.05513M -
Total cash from financing activities 4.74M 19.18M 0.86M 0.06M 1.91M
Change to operating activities 0.76M -1.00636M -0.04300M -0.07000M -0.63187M
Net income -6.98888M -1.29589M -1.28460M -0.62958M -3.77592M
Change in cash -3.48196M 14.65M 0.11M -0.20141M 0.20M
Begin period cash flow 13.89M 0.13M 0.06M 0.26M 0.06M
End period cash flow 10.41M 14.79M 0.17M 0.06M 0.26M
Total cash from operating activities -8.81830M -4.75484M -0.72840M -0.24958M -1.55536M
Issuance of capital stock 5.05M 22.80M 0.90M 0.00000M 1.96M
Depreciation 0.06M 0.01M 0.02M 0.02M 0.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.04361M -0.02917M -0.04300M 0.01M -0.02006M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.27227M 1.30M -0.04459M 0.06M -0.04913M
Change to netincome -4.52494M -3.05135M 0.17M 0.06M 2.88M
Capital expenditures 0.04M 0.03M 0.01M 0.00704M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.45M -1.07979M 0.36M 0.30M -0.67402M
Stock based compensation 0.47M 0.39M 0.29M 0.03M 0.28M
Other non cash items -3.80009M -2.78467M -0.11990M 0.04M 2.60M
Free cash flow -8.86252M -4.78606M -0.74275M -0.25662M -1.59643M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
XRTX
XORTX Therapeutics Inc		 -0.08 3.56% 2.17 - 0.96 - 1.60 -1.1018
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.

XORTX Therapeutics Inc

3710 ? 33rd Street NW, Alberta Beach, AB, Canada, T2L 2M1

Key Executives

Name Title Year Born
Dr. Allen Warren Davidoff Ph.D. Founder, CEO, Pres & Director 1960
Mr. Amar Keshri C.A., CPA Chief Financial Officer 1979
Nick Rigopoulos Director of Communications NA
Dr. David Sans M.B.A., Ph.D. Director of Corp. Devel. NA
Dr. Stephen Haworth M.D., MRCP Chief Medical Officer 1951
Dr. David MacDonald Ph.D. Consultant of Clinical Operations 1963
Dr. Stacy Evans M.B.A., M.D. Chief Bus. Officer NA
Ms. Charlotte May Corp. Sec. NA
Dr. Allen Warren Davidoff Ph.D. Founder, CEO, President & Director 1960
Mr. James Neville Fairbairn C.A., C.P.A., ICD.D Interim Chief Financial Officer 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions